Cohance Lifesciences has granted 389,668 stock options to eligible employees under its Employee Stock Option Plan 2023 (ESOP 2023). This includes 218,077 stock options related to the Scheme of Amalgamation with erstwhile Cohance Lifesciences Limited, approved on March 27, 2025. Vesting details and other terms are governed by ESOP 2023.
ESOP Grant Details
Cohance Lifesciences has approved the grant of 389,668 stock options to eligible employees under the Employee Stock Option Plan 2023 (“ESOP 2023”). This decision was made by the Nomination and Remuneration Committee on January 17, 2026.
Scheme of Amalgamation
The grant includes 218,077 stock options related to the Scheme of Amalgamation between Cohance Lifesciences Limited (Transferor Company) and the Company. The Hon’ble National Company Law Tribunal (“NCLT”) approved the scheme on March 27, 2025.
Vesting Period
171,591 of the options granted shall vest between a minimum of 1 year and a maximum of 10 years from the grant date. Vesting is subject to conditions outlined in the grant letter provided to employees.
Regarding the 218,077 options granted in lieu of stock options from the Transferor Company, the period during which employees held options in the Transferor Company will be considered for determining the vesting period. These options, originally granted on March 14, 2023 and/or February 26, 2024, will vest on April 1, 2026.
Exercise Period
The exercise period for the options is up to 3 years from the date of vesting.
Source: BSE
